ARBLI (Losartan Potassium) Patent Expiration, LOE Window & CMS Spending

ARBLI (Losartan Potassium) by Scienture: FDA Orange Book core substance LOE 2041-10-07, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $595 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorScienture
FDA Application & PathwayN218772 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2041-10-07
Last Listed Patent or Exclusivity Date2041-10-07
Orange Book Patents (*PED Extensions)6 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($595 intro WAC)